Giuseppe Gritti

Scopus Publications

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (Blood Cancer Journal, (2025), 15, 1, (129), 10.1038/s41408-025-01329-2)
Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, et al.
Blood Cancer Journal, 2026
Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy
Pier Luigi Zinzani, Giulia Dell’Omo, Letizia Fusco, Ilaria Peduto, Carlotta Galeone, et al.
Hematological Oncology, 2026
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy
Daniela Estefania Banegas, Isacco Ferrarini, Andrea Bernardelli, Alessia Moioli, Vittorio Ruggero Zilioli, et al.
Leukemia and Lymphoma, 2026
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma
Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani, Nancy L. Bartlett, Jacob H. Christensen, et al.
Blood Advances, 2025
In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment–based response, and correlated with PFS per investigator and OS. PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review. Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms. Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4. In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status. Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients. In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms. This trial was registered at www.ClinicalTrials.gov as #NCT01777152.
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, et al.
Journal of Clinical Oncology, 2025
PURPOSE An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283 ) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy. METHODS Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2–6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2–12 (21-day cycles; once daily). Polatuzumab vedotin was given for six fixed-duration cycles, and glofitamab for 12. RESULTS As of September 2, 2024, 129 patients with LBCL (HGBCL; n = 44, 34.1%), received ≥1 dose of study treatment. The median age was 67 years (range, 23-84), and 63.6% were male. Patients had received a median of 2 (range, 1-7) previous lines of treatment (previous CAR T-cell therapy, n = 28, 21.7%). The independent review committee–assessed overall response rate was 78.3% (complete response rate, 59.7%). The median progression-free survival and overall survival (OS) were 12.3 and 33.8 months, respectively (median OS follow-up time, 32.7 months). The most common adverse event (AE) was cytokine release syndrome (43.4%; grade 1-2: 41.9%; one grade 5 event). Grade 3-4 AEs occurred in 58.9% of patients; 9.3% had grade 5 AEs, and 14.7% discontinued treatment because of AEs. CONCLUSION Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure.
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, et al.
Blood Cancer Journal, 2025
Trial registration: ClinicalTrials.gov number: NCT01777152
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
Federico Lussana, Chiara F. Magnani, Stefania Galimberti, Giuseppe Gritti, Giuseppe Gaipa, et al.
Blood Cancer Journal, 2025
Enhancing the diagnostic accuracy of core needle biopsy in patients with lymphoproliferative disorders by an optimized protocol
Silvia Ferrari, Alessandra Weber, Paolo Marra, Paola Tebaldi, Chiara Pavoni, et al.
Radiologia Medica, 2025
Purpose Surgical excision biopsy of lymph nodes stands as the gold standard for histological characterization of lymphoproliferative disorders (LD). However, contemporary clinical practice increasingly leans toward core needle biopsy (CNB). This study seeks to explore the factors influencing the diagnostic yield of CNB in LD. Material and Methods This unicentric retrospective study presents data from patients referred for suspicion of new or relapsing LD. All patients underwent image-guided CNB of the target lesion based on PET/CT findings. The primary endpoint was the diagnostic outcome, comparing the ability to achieve a definitive diagnosis according to international guidelines with CNB versus the necessity for subsequent excisional biopsy. Results We enrolled 478 consecutive patients undergoing CNB, categorized into two cohorts. Cohort A comprised patients who underwent CNB using 18-20G full-core Menghini needles, with a median macroscopic fragment dimension of 1 cm. Cohort B included patients who underwent CNB with 16-18G semiautomatic guillotine needles, with a median macroscopic fragment dimension of 1.5 cm. In cohort A, the rates of diagnostic and non-diagnostic (or non-sufficiently detailed) CNBs were 95 (73%) versus 35 (27%), respectively. In cohort B, these rates were 299 (86%) versus 49 (14%). Conclusion The type and size of the needle used for CNB, as well as the histologic variant of LD, emerged as factors influencing diagnostic yield and accuracy. Given the swiftness of CNB compared to surgical excision, optimizing this technique could streamline the diagnostic and therapeutic workflow for patients with suspected LD.
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia
Nicola Maciocia, Malika Hoekx, Ciaran Acuna, Brandon Wade, Amy Burley, et al.
Science Translational Medicine, 2025
Patients with relapsed/refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) have a dismal prognosis, highlighting the urgent need for effective therapies. Chimeric antigen receptor (CAR)–T cell approaches targeting pan–T cell antigens may be limited by T cell aplasia and fratricide, necessitating “rescue” allogeneic hematopoietic stem cell transplantation. In this study, we identify CD21, a pan–B cell marker, as a promising target for T-ALL immunotherapy. CD21 is expressed in 50% of T-ALL cases at diagnosis but in fewer than 10% of mature T cells. We observed that CAR-T cells targeting membrane-distal CD21 epitopes were ineffective, likely because of the bulky, glycosylated nature of the antigen. However, when we engineered CAR-T cells to target membrane-proximal CD21 epitopes using an antigen-binding fragment (Fab)–CAR design, we demonstrated robust activity against T-ALL cell lines, primary tumors, and patient-derived xenografts in both in vitro and in vivo models. The enhanced efficacy of this Fab-CAR design was driven by its high stability and reduced surface expression, addressing limitations of traditional CAR constructs. In addition, pharmacological inhibition of the phosphatidylinositol 3-kinase axis up-regulated CD21 expression in T-ALL, further enhancing the potency of anti-CD21 CAR-T cells in vitro and in a patient-derived xenograft in vivo model. This study establishes CD21 as a viable CAR-T target and highlights advances in CAR design for bulky antigens, as well as the potential for pharmacological strategies to augment target expression. Anti-CD21 CAR-T cells represent a promising therapeutic option for improving outcomes for patients with T-ALL.
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
Giuseppe Gritti, Silvia Ferrari, Federico Lussana, Anna Maria Barbui, Francesco Landi, et al.
Blood Cancer Journal, 2024
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma
A. Pinto, M. Caltagirone, M. Battista, G. C. Gazzoli, C. Patti, et al.
British Journal of Haematology, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, et al.
Lancet Oncology, 2024
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
Giuseppe Gritti, Anton Belousov, James Relf, Mark Dixon, Maneesh Tandon, et al.
Blood Advances, 2024
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Sam Yuen, Tycel J. Phillips, Rajat Bannerji, Paula Marlton, Giuseppe Gritti, et al.
American Journal of Hematology, 2024
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences
Silvia Alberti Violetti, Marco Ardigò, Paolo Fava, Giuseppe Gritti, Erika Morsia, et al.
Drugs in Context, 2024
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, et al.
Blood Advances, 2023
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Emmanuel Bachy, Kerry J. Savage, Huiqiang Huang, Yok-Lam Kwong, Giuseppe Gritti, et al.
Blood Advances, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A. Lasater, Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, et al.
American Journal of Hematology, 2023
Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659
Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, et al.
Oncotarget, 2023
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Alejandro Martín García-Sancho, Monica Bellei, Miriam López-Parra, Giuseppe Gritti, María Cortés, et al.
Haematologica, 2022
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma
Yeman B. Hagos, Ayse U. Akarca, Alan Ramsay, Riccardo L. Rossi, Sabine Pomplun, et al.
Hematological Oncology, 2022
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
Paul M. Maciocia, Patrycja A. Wawrzyniecka, Nicola C. Maciocia, Amy Burley, Thaneswari Karpanasamy, et al.
Blood, 2022
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, Anna Maria Anastasi, Gianfranco Battistuzzi, et al.
Molecular Therapy, 2022
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, et al.
Blood, 2022
Chimeric antigen receptor T cells for gamma–delta T cell malignancies
P. A. Wawrzyniecka, L. Ibrahim, G. Gritti, M. A. Pule, P. M. Maciocia
Leukemia, 2022
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis
Luca Ceriani, Lisa Milan, Luciano Cascione, Giuseppe Gritti, Federico Dalmasso, et al.
Hematological Oncology, 2022
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface
Yeman Brhane Hagos, Ayse U Akarca, Alan Ramsay, Riccardo L Rossi, Sabine Pomplun, et al.
Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics, 2022
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, et al.
Journal of Translational Medicine, 2021
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x)
Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, et al.
Leukemia, 2021
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, et al.
Leukemia, 2021
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure
Marianna Damiani, Lucia Gandini, Francesco Landi, Gianmaria Borleri, Fabrizio Fabretti, et al.
Respiratory Medicine, 2021
Skip pattern approach toward the early access of innovative anticancer drugs
G. Apolone, A. Ardizzoni, A. Biondi, A. Bortolami, C. Cardone, et al.
ESMO Open, 2021
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, et al.
Blood, 2021
Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell–redirected bispecific antibodies
Federico Lussana, Giuseppe Gritti, Alessandro Rambaldi
Journal of Clinical Oncology, 2021
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19
Enrico Brunetta, Marco Folci, Barbara Bottazzi, Maria De Santis, Giuseppe Gritti, et al.
Nature Immunology, 2021
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
Blood, 2020
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, et al.
Journal of Translational Medicine, 2020
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, et al.
Journal of Clinical Investigation, 2020
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
Alessandro Rambaldi, Giuseppe Gritti, Maria Caterina Micò, Marco Frigeni, Gianmaria Borleri, et al.
Immunobiology, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C
Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, Silvia Ferrari, et al.
Clinical Cancer Research, 2020
Erratum: SAKK38/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model (Blood Advances (2020) 4:6 (1082-1092) DOI: 10.1182/bloodadvances.2019001201)
Blood Advances, 2020
SAKK38/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model
Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, Angela Polino, et al.
Blood Advances, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, et al.
Blood Advances, 2020
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
E. González-Barca, A. Boumendil, D. Blaise, M. Trněný, T. Masszi, et al.
Bone Marrow Transplantation, 2020
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma
Andreas Viardot, Georg Hess, Ralf C. Bargou, Nicholas J. Morley, Giuseppe Gritti, et al.
Leukemia and Lymphoma, 2020
Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Efficacy and safety from the phase II checkmate 436 study
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, et al.
Journal of Clinical Oncology, 2019
Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy [Oncotarget. 9 (2018) (9766-9775)] doi: 10.18632/oncotarget.23919
Giuseppe Gritt, Andrea Gianatt, Fiorella Petronzeii, Rita De Santis, Chiara Pavoni, et al.
Oncotarget, 2018
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients
Nicola S. Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M. Pelizzari, Paola Tozzi, et al.
Hematological Oncology, 2018
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
Giuseppe Gritti, Andrea Gianatti, Fiorella Petronzelli, Rita De Santis, Chiara Pavoni, et al.
Oncotarget, 2018
Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma
Alessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, Benedetta Puccini, Caterina Patti, et al.
Haematologica, 2017
Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era?
Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi
Mediterranean Journal of Hematology and Infectious Diseases, 2017
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M Maciocia, Patrycja A Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U Akarca, et al.
Nature Medicine, 2017
Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, et al.
Oncotarget, 2017
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas
Sergio Cortelazzo, Corrado Tarella, Alessandro Massimo Gianni, Marco Ladetto, Anna Maria Barbui, et al.
Journal of Clinical Oncology, 2016
A data-driven network model of primary myelofibrosis: Transcriptional and post-transcriptional alterations in CD34+ cells
E Calura, S Pizzini, A Bisognin, A Coppe, G Sales, et al.
Blood Cancer Journal, 2016
Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas
Giuseppe Gritti, Cristina Boschini, Andrea Rossi, Federica Delaini, Anna Grassi, et al.
Plos One, 2015
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: Implications for combination therapy
F. D. Roit, P. J. Engelberts, R. P. Taylor, E. C. W. Breij, G. Gritti, et al.
Haematologica, 2015
Rate of primary refractory disease in B and T-Cell non-Hodgkin's Lymphoma: Correlation with long-term survival
Corrado Tarella, Angela Gueli, Federica Delaini, Andrea Rossi, Anna Maria Barbui, et al.
Plos One, 2014
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial
A Cortelezzi, M Sciumè, A M Liberati, D Vincenti, A Cuneo, et al.
Leukemia, 2014
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, Federica Delaini, Elena Oldani, et al.
American Journal of Hematology, 2013
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia
Gianluigi Reda, Francesco Maura, Giuseppe Gritti, Anna Gregorini, Francesca Binda, et al.
American Journal of Hematology, 2012
Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: Clinical report of three patients
Roberto Castelli, Giuseppe Gritti, Antonino Cannavò, Guido Moreo, Giancarlo Conti, et al.
Immunopharmacology and Immunotoxicology, 2012
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
Giuseppe Gritti, Gianluigi Reda, Francesco Maura, Alfonso Piciocchi, Luca Baldini, et al.
Leukemia and Lymphoma, 2012
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
Agostino Cortelezzi, Giuseppe Gritti, Luca Laurenti, Antonio Cuneo, Stefania Ciolli, et al.
British Journal of Haematology, 2012
Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis
Giuseppe Gritti, Agostino Cortelezzi, Paolo Bucciarelli, Francesca Rezzonico, Silvia Lonati, et al.
American Journal of Hematology, 2011
Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status [7]
A Cortelezzi, G Gritti, N Del Papa, M C Pasquini, R Calori, et al.
Leukemia, 2008

Giuseppe Gritti

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications